文献速递其他结缔组织病

影响系统性硬化症随机临床试验招募速度的试验层面因素

Trial-level factors affecting accrual rate of systemic sclerosis randomized clinical trials.
PubMed 文献 · Semin Arthritis Rheum · 2025-05-03

该研究检索2000至2024年PubMed收录的系统性硬化症随机对照试验,纳入80项在新冠疫情前完成招募的研究,估算入组时间与招募速度。中位招募时间15个月,中位招募速度3.1例/月;多因素分析显示招募速度与偏斜随机化、盲法、非企业资助、国际招募及同时纳入局限型和弥漫型患者正相关。

要点

  • 80项系统性硬化症随机对照试验中位招募时间15个月,中位招募速度3.1例/月。
  • 招募速度在2000年代初较快、2012年后较快,中间时段较慢。
  • 多因素分析显示偏斜随机化、盲法、非企业资助、国际招募及纳入两种亚型与招募速度正相关。

核心结论

  • 过去20年系统性硬化症随机对照试验的患者招募总体缓慢,且随时间无显著改善。

研究设计与样本

  • 检索2000至2024年PubMed收录的系统性硬化症随机对照试验,纳入招募在新冠 pandemic 前完成的80项研究。
  • 记录国家、分期、随机化比例、干预、盲法、资金来源、结局类型及入组年份,计算入组时长与招募速度(例/月),采用多变量负二项广义线性模型分析影响因素。

主要发现

  • 80项研究中单国研究占75.0%,企业资助占57.5%,主要招募地区为欧洲(36.2%)和北美(22.5%)。
  • 65%的研究同时纳入局限型和弥漫型系统性硬化症患者,中位样本量40.5例,20%的随机对照试验入组≥100例。
  • 中位招募时间15个月(IQR 9.9-30.0),中位招募速度3.1例/月(IQR 1.6-5.5)。
  • 招募速度随时间变化,2000年代初较快、2012年后较快,中间时段较慢。
  • 多变量分析显示招募速度与偏斜随机化、盲法、非企业资助、国际招募及同时纳入两种亚型正相关,尤其相对于仅纳入弥漫型皮肤型系统性硬化症患者的研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the average time to complete patient enrollment and identify factors associated with accrual rates in systemic sclerosis (SSc) randomized controlled trials (RCTs). METHODS: We searched published SSc-RCTs indexed in PubMed from 2000 to 2024, selecting those with recruitment completed before the COVID-19 pandemic. We recorded key trial features (country, phase, randomization ratio, intervention, blinding, funding source, outcome type) and enrollment year(s). We measured enrollment duration and accrual rate (participants per month). A multivariable negative binomial generalized linear model was used to identify factors associated with accrual rate. RESULTS: We included 80 studies, mostly single-country (75.0 %) and industry-funded (57.5 %), mainly recruiting in Europe (36.2 %) and North America (22.5 %). In 65 % of studies, both limited and diffuse SSc patients were enrolled. The median sample size was 40.5 patients, with 20 % of RCTs enrolling ≥100 patients. The median recruitment time was 15 months (IQR 9.9 - 30.0), with a median accrual rate of 3.1 (IQR 1.6 - 5.5) participants per month. Recruitment rates varied over time, with faster accrual early in the 2000s and after 2012, and a slower period in between. Multivariable analysis showed that accrual rate was positively associated with skewed randomization, blinding, non-industry funding, international recruitment, and inclusion of both SSc subsets, especially compared to studies involving only dcSSc patients. CONCLUSIONS: Recruiting SSc patients for RCTs has been challenging, with generally slow accrual over the past 20 years and no significant improvement over time.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Russo B, Chirică IS, Courvoisier DS, et al. Trial-level factors affecting accrual rate of systemic sclerosis randomized clinical trials. Semin Arthritis Rheum. 2025. PMID: 40349419. doi:10.1016/j.semarthrit.2025.152749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。